Inovio Pharmaceuticals, Inc. News (NASDAQ:INO)

DateTimeSource
Headline
05/24/20178:00AMGLOBEInovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study
PLYMOUTH MEETING, Pa., May 24, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine. The vaccine candidate, PENNVAX-GP... More...>>
05/10/20178:00AMGLOBEInovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer
PLYMOUTH MEETING, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced MedImmune, AstraZeneca’s global biologics research and development arm, will start a new clinical trial investigating the combination of MEDI0457, an immunotherapy designed to generate antigen specific killer... More...>>
05/08/20177:30AMPRNUSRegeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy Phase 1b/2a clinical trial will combine Regeneron's PD-1 inhibitor REGN2810 and Inovio's T cell activator INO-5401 and immune activator INO-9012 in brain cancer PR Newswire TARRYTOWN, N.Y. and PLYMOUTH MEETING, Pa... More...>>
05/08/20177:30AMGLOBEInovio & Regeneron Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
PLYMOUTH MEETING, Pa. and TARRYTOWN, N.Y., May 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced a clinical study agreement for a phase 1b/2a immuno-oncology trial. The study will be conducted by Inovio in patients with newly diagnosed... More...>>
05/02/20178:00AMGLOBEInovio Pharmaceuticals to Participate in Bank of America Merrill Lynch 2017 Healthcare Conference
PLYMOUTH MEETING, Pa., May 02, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will participate in the Bank of America Merrill Lynch 2017 Healthcare Conference May 16-18th, 2017 in Las Vegas, NV. Dr. J. Joseph Kim, President and CEO of Inovio, will host one-on-one meetings with... More...>>
04/26/20178:00AMGLOBEInovio Pharmaceuticals to Report First Quarter 2017 Financial Results May 10, 2017
PLYMOUTH MEETING, Pa., April 26, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 first quarter financial results on Wednesday, May 10, 2017 at 4:30 p.m. ET. A live and archived version of the audio presentation will... More...>>
04/24/20178:00AMGLOBEInovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers
New study expands VGX-3100 program for evaluating therapeutic applications in HPV-related pre-cancers with high medical need VGX-3100 previously demonstrated efficacy in regressing HPV-related cervical pre-cancer PLYMOUTH MEETING, Pa., April 24, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO... More...>>
04/11/20179:00AMGLOBEInovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Expanded Clinical Trial
PLYMOUTH MEETING, Pa., April 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today preliminary results from the expanded stage of its phase I study, EBOV-001. The expanded study examined different regimens of its Ebola DNA vaccine INO-4201 using intradermal (skin) administration. The results... More...>>
03/30/20178:00AMGLOBEInovio and Collaborators Receive NIH Grant to Evaluate HIV Immunotherapy PENNVAX®-GP’s Ability to Induce Remission of HI...
PLYMOUTH MEETING, Pa., March 30, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its academic and industry collaborators received a multi-year $6.95 million grant from the NIH’s National Institute of Allergy and Infectious Diseases to develop a single or combination therapy using... More...>>
03/21/20178:00AMGLOBEGeorge Bickerstaff Elected to Inovio’s Board of Directors
PLYMOUTH MEETING, Pa., March 21, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today the election of George Bickerstaff to its Board of Directors.  Mr. Bickerstaff is an internationally recognized expert in finance, healthcare and information technology.  He has served Novartis... More...>>
03/15/20174:05PMGLOBEInovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results
PLYMOUTH MEETING, Pa., March 15, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the fourth quarter and year ended December 31, 2016. Total revenue was $8.5 million and $35.4 million for the quarter and year ended December 31, 2016, as compared to $5.9 million and... More...>>
03/09/20178:00AMGLOBEInovio Pharmaceuticals to Report Fourth Quarter and Year End 2016 Financial Results on March 15, 2017
PLYMOUTH MEETING, Pa., March 09, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to discuss its 2016 fourth quarter and year end financial results and provide a corporate update on Wednesday, March 15, 2017 at 4:30 p.m. ET. A live and... More...>>
02/27/20177:00AMGLOBEInovio’s SynCon® WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy
PLYMOUTH MEETING, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its SynCon® WT1 cancer immunotherapy was capable of breaking immune tolerance and inducing neo-antigen-like T cell responses to cause tumor regression in pre-clinical studies. Breaking tolerance has... More...>>
02/23/20177:00AMGLOBEInovio Reports New Positive Clinical Data on Vaccine Advances in the Fight Against Emerging Infectious Diseases
Significant immune responses observed in 100% of Zika-vaccinated subjects and 98% of MERS-vaccinated human subjects in separate phase I studies  Data reported at Coalition for Epidemic Preparedness Innovation (CEPI) meeting PLYMOUTH MEETING, Pa., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO... More...>>
02/13/20176:00AMGLOBEInovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer Immunotherapy VGX-3100 in Greater ...
PLYMOUTH MEETING, Pa., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has entered into a collaboration and license agreement providing ApolloBio Corporation (NEEQ:430187) with the exclusive right to develop and commercialize VGX-3100, Inovio’s DNA immunotherapy product... More...>>
01/30/20178:00AMGLOBEInovio Pharmaceuticals to Participate in Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences: BIO CEO & Investor ConferenceFireside chatDr. J. Joseph Kim, President & CEO10:00AM ET, February 13, 2017The Waldorf... More...>>
12/21/20168:00AMGLOBEInovio’s Zika Vaccine Generates Robust Immune Responses in First Human Study
PLYMOUTH MEETING, Pa., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based Zika vaccine (GLS-5700) generated robust antigen-specific antibody responses in a first-in-man, multi-center phase I trial. In initial testing, Zika-naïve subjects in both low dose and high... More...>>
12/06/20168:00AMGLOBEInovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute
PLYMOUTH MEETING, Pa., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the International Vaccine Institute (IVI) will provide new funding and support to further advance GLS-5300, Inovio’s vaccine to prevent Middle East Respiratory Syndrome (MERS) virus infection. Inovio... More...>>
12/01/20169:00AMGLOBEInovio Pharmaceuticals Awarded $6.1 Million Sub-grant Through Wistar Institute to Develop DNA-based Monoclonal Antibodies Aga...
Grant Provides Funding to Help Prepare New Zika Therapy for Human Trials Inovio Already in Two Human Trials for its Preventive Zika Vaccine PLYMOUTH MEETING, Pa. & PHILADELPHIA, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has been awarded a $6.1 million sub-grant... More...>>
11/25/20168:00AMGLOBEInovio Applies to Cease Reporting to Canadian Securities Regulatory Authorities; NASDAQ Listing and US Reporting Unaffected
PLYMOUTH MEETING, Pa., Nov. 25, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that further to the voluntary delisting of Genetronics Biomedical Corporation, a predecessor of the Company, from the Toronto Stock Exchange on January 17, 2003, it has applied to the British Columbia Securities... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:us D:20170525 21:52:32